Cubist Systematic Strategies’s Matinas BioPharma MTNB Stock Holding History

Cubist Systematic Strategies’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-396	Closed	-$20K	–	3699
2021 Q4	$20K	Buy	396 +144	+57%	+$7.7K	﹤0.01%	3376
2021 Q3	$16K	Buy	+252	New	+$10.9K	﹤0.01%	2895
2021 Q2	–	Sell	-744	Closed	-$39K	–	3026
2021 Q1	$39K	Buy	+744	New	+$49.9K	﹤0.01%	2745

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Cubist Systematic Strategies's MTNB Position: Q1 2022 in Review

Cubist Systematic Strategies sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 396 shares — an estimated $20K sold.

Cubist Systematic Strategies first reported a position in MTNB in Q1 2021 and held it in 3 quarters. The position peaked at $39K in Q1 2021. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

Cubist Systematic Strategies reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 396 Matinas BioPharma shares in Q1 2022, an estimated $20K.
Cubist Systematic Strategies first reported a position in Matinas BioPharma in Q1 2021 and held it in 3 quarters.
Cubist Systematic Strategies's Matinas BioPharma position peaked at $39K in Q1 2021.
56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Cubist Systematic Strategies's 13F filing for Q1 2022, filed 16 May 2022.